TD Asset Management
ONCY

TD Asset Management’s Oncolytics Biotech ONCY Stock Holding History

TD Asset Management’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-52,007
Closed -$120K – 1546
2021
Q2 		$120K Buy
+52,007
New +$159K ﹤0.01% 1498

Other funds holding ONCY

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TD Asset Management's ONCY Position: Q3 2021 in Review

TD Asset Management sold out of Oncolytics Biotech (ONCY) in Q3 2021, closing a stake of 52,007 shares — an estimated $120K sold.

TD Asset Management first reported a position in ONCY in Q2 2021 and held it in 1 quarter. The position peaked at $120K in Q2 2021. 37 funds tracked by Wall St. Rank hold ONCY as of Q3 2021.

  • TD Asset Management reported no remaining Oncolytics Biotech position as of Q3 2021 after selling out during the quarter.
  • TD Asset Management sold 52,007 Oncolytics Biotech shares in Q3 2021, an estimated $120K.
  • TD Asset Management first reported a position in Oncolytics Biotech in Q2 2021 and held it in 1 quarter.
  • TD Asset Management's Oncolytics Biotech position peaked at $120K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q3 2021.

Based on TD Asset Management's 13F filing for Q3 2021, filed 9 Nov 2021.